CU22629A1 - Formulaciones inmunopotenciadoras para uso vacunal - Google Patents

Formulaciones inmunopotenciadoras para uso vacunal

Info

Publication number
CU22629A1
CU22629A1 CU1997027A CU1997027A CU22629A1 CU 22629 A1 CU22629 A1 CU 22629A1 CU 1997027 A CU1997027 A CU 1997027A CU 1997027 A CU1997027 A CU 1997027A CU 22629 A1 CU22629 A1 CU 22629A1
Authority
CU
Cuba
Prior art keywords
formulation
elements
decrease
immune response
respect
Prior art date
Application number
CU1997027A
Other languages
English (en)
Inventor
Pardillo Circe Mesa
Buch Antonieta Herrera
Portilla Tania Carmenate
Perez Enrique Iglesias
Diaz Dagmara Pichardo
Ricondo Luis Javier Cruz
Martinez Maylin Diaz
Gay Maydel Hechavarria
Rio Gloria Veliz
Rubido Julio Cesar Aguilar
Angulo Maria De Jesus Leal
Pinol Juan Joel Madrazo
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1997027A priority Critical patent/CU22629A1/es
Priority to PCT/CU1998/000003 priority patent/WO1998039032A1/es
Priority to US09/380,790 priority patent/US6355414B1/en
Priority to ZA981897A priority patent/ZA981897B/xx
Priority to CNB988041456A priority patent/CN1161154C/zh
Priority to DE69830156T priority patent/DE69830156T2/de
Priority to AT98907815T priority patent/ATE295182T1/de
Priority to BR9808832-7A priority patent/BR9808832A/pt
Priority to AU66077/98A priority patent/AU6607798A/en
Priority to CA002283344A priority patent/CA2283344A1/en
Priority to ES98907815T priority patent/ES2241122T3/es
Priority to MYPI98000960A priority patent/MY132817A/en
Priority to EP98907815A priority patent/EP0971737B1/en
Priority to ARP980101012A priority patent/AR009866A1/es
Priority to HK00105771A priority patent/HK1026626A1/xx
Publication of CU22629A1 publication Critical patent/CU22629A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con la rama de la medicina, particularmente con un nuevo adyuvante que permita la potenciación de la respuesta inmune a antígenos vacunales. El objetivo técnico que se persigue con la invención propuesta es precisamente el desarrollo de una formulación capaz de elevar los niveles de respuesta inmune del organismo a antígenos vacunales con el uso de elementos de un alto grado de pureza y que presentan una actividad sinérgica en dicha formulación. Para lograr este objetivo se emplea esencialmente una combinación de dos elementos: una sal de calcio, preferentemente el oxalato de calcio quimícamente puro y un polisacárido inmunoestimulante preferentemente el polisacárido del gel de Aloe barbadensis Miller. Otros elementos, reguladores del tamano de la partícula de oxalato de calcio, pueden ser introducidos en la formulación. La formulación objeto de esta invención, permite obtener elevadas respuestas de anticuerpos, evidenciando una actividad sinérgica reportada por primera vez entre dichas partículas y el inmunoestimulante. La diferencia entre el poder adyuvante de la formulación con respecto a los elementos por separado, es amplia. La formulación objeto de la presente invención es aplicable en la industria farmaceútica, para la elaboración de vacunas tanto para uso en humanos como en animales, a las que les confiere una mayor inmunogenicidad, permitiendo disminuir el número de inyecciones, disminuir la cantidad de antígeno por dosis y potenciar la respuesta de mucosas cuando es usada por esta vía. Además, la formulación en cuestión es factible en cualquier situación donde se desee introducir antígenos, tanto por vía mucosal como sistémica, aprovechando el vehículo o sistema particulado y las propiedades adhesivas de este compuesto con respecto a las células epiteliales.
CU1997027A 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal CU22629A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal
PCT/CU1998/000003 WO1998039032A1 (es) 1997-03-06 1998-03-05 Formulaciones inmunopotenciadoras para uso vacunal
US09/380,790 US6355414B1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
ZA981897A ZA981897B (en) 1997-03-06 1998-03-05 Formualtions for immunological potentiation of vaccines
CNB988041456A CN1161154C (zh) 1997-03-06 1998-03-05 用于疫苗的免疫增强制剂
DE69830156T DE69830156T2 (de) 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen
AT98907815T ATE295182T1 (de) 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen
BR9808832-7A BR9808832A (pt) 1997-03-06 1998-03-05 Formulações de vacina para uso nasofarìngeo, uso mucosal e uso sistêmico
AU66077/98A AU6607798A (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
CA002283344A CA2283344A1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
ES98907815T ES2241122T3 (es) 1997-03-06 1998-03-05 Formulaciones de inmunopotenciacion para uso como vacunas.
MYPI98000960A MY132817A (en) 1997-03-06 1998-03-05 Formulations for immunological potentiation of vaccines
EP98907815A EP0971737B1 (en) 1997-03-06 1998-03-05 Immunopotentiating formulations for vaccinal use
ARP980101012A AR009866A1 (es) 1997-03-06 1998-03-06 Formulacion inmunopotenciadora para uso vacunal
HK00105771A HK1026626A1 (en) 1997-03-06 2000-09-14 Immunopotentiating formulations for vaccinal use.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal

Publications (1)

Publication Number Publication Date
CU22629A1 true CU22629A1 (es) 2000-12-22

Family

ID=5459228

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal

Country Status (15)

Country Link
US (1) US6355414B1 (es)
EP (1) EP0971737B1 (es)
CN (1) CN1161154C (es)
AR (1) AR009866A1 (es)
AT (1) ATE295182T1 (es)
AU (1) AU6607798A (es)
BR (1) BR9808832A (es)
CA (1) CA2283344A1 (es)
CU (1) CU22629A1 (es)
DE (1) DE69830156T2 (es)
ES (1) ES2241122T3 (es)
HK (1) HK1026626A1 (es)
MY (1) MY132817A (es)
WO (1) WO1998039032A1 (es)
ZA (1) ZA981897B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20060105063A1 (en) * 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
AU2006238906B2 (en) 2005-04-25 2013-04-11 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
AR064359A1 (es) 2006-12-15 2009-04-01 Ca Nat Research Council Agregados de lipidos polares de arqueas para administracion a animales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
ZA93216B (en) * 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
DK0835663T3 (da) * 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JPH08183742A (ja) * 1994-12-28 1996-07-16 Dai Ichi Seiyaku Co Ltd 経鼻ワクチンリポソーム
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
ATE295182T1 (de) 2005-05-15
ES2241122T3 (es) 2005-10-16
DE69830156T2 (de) 2006-01-26
CN1252002A (zh) 2000-05-03
BR9808832A (pt) 2000-07-04
HK1026626A1 (en) 2000-12-22
MY132817A (en) 2007-10-31
EP0971737A1 (en) 2000-01-19
EP0971737B1 (en) 2005-05-11
CN1161154C (zh) 2004-08-11
AR009866A1 (es) 2000-05-03
AU6607798A (en) 1998-09-22
ZA981897B (en) 1998-09-07
CA2283344A1 (en) 1998-09-11
US6355414B1 (en) 2002-03-12
WO1998039032A1 (es) 1998-09-11
DE69830156D1 (de) 2005-06-16

Similar Documents

Publication Publication Date Title
ES2331952T3 (es) Fraccion de quil a con baja toxicidad y su uso.
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
JP2997073B2 (ja) 鼻腔内または吸入投与用ワクチン製剤およびその製造方法
ATE243530T1 (de) Virus impfstoff
WO1991001143A1 (en) Stable vaccine compositions containing interleukins
Zhang et al. A protein vaccine with alum/c-GAMP/poly (I: C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern
CU22629A1 (es) Formulaciones inmunopotenciadoras para uso vacunal
Hassan et al. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
Chand et al. Polyphosphazenes as adjuvants for animal vaccines and other medical applications
ES2645076T3 (es) Adyuvante
ES2894138T3 (es) Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ES2329118T3 (es) Ltb4 como adyuvante de vacuna.
MXPA03009515A (es) Vacunas que incluyen como adyuvante ifn del tipo i, y procesos relacionados con ellas.
ES2938847T3 (es) Composiciones para la inducción de la respuesta inmunitaria
BR0115859A (pt) Método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
ES2082201T3 (es) Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
CU22740A1 (es) Formulación de ácidos nucleicos y acemanano
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
Phillips et al. Modulation of murine macrophage nitric oxide synthesis by liposomal phospholipids: correlation with liposome immune adjuvant activity
KR20010040932A (ko) 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신
Ngu Human cancers and viruses: A hypothesis for immune destruction of tumours caused by certain enveloped viruses using modified viral antigens
Kimoto et al. Induction of systemic, mucosal and cellular immunity against SARS-CoV-2 in mice intratracheally vaccinated with a viral S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10
Jones et al. Subcellular Location Of MAC-1 (CR-3) In Human Neutrophils: Effects Of Chemotactic Factors And PMA